UNSPSC 51271917: Chloroprocaine penicillin o

This classification denotes an anesthetic agent with the molecular formula C13H19ClN2O2.C13H18N2O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O3NVO08Z59, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-(((2-propenylthio)acetyl)amino)-, (2s,5r,6r)-, compd. with 2-(diethylamino)ethyl 4-amino-2-chlorobenzoate (1:1), but more generally known as chloroprocaine penicillin o, which bears US NIH Compound Identifier 11329.

European Medicines Agency schedules chloroprocaine penicillin o or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06193MIG. Most nations, for tariff purposes, schedule chloroprocaine penicillin o under HS 29224995. SMILES: CCN(CC)CCOC(=O)C1CCC(CC1CL)N.CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CSCC=C)C(=O)O)C.

UNSPSC 51271917 Chloroprocaine penicillin o is a Commodity code under which state and local health and human services agencies procure branded and generic pharmaceutical products, including antibiotics and penicillin-class drugs, for distribution through government health facilities and cooperative purchasing arrangements. Recent activity centers on multi-source generic pharmaceutical aggregation contracts rather than procurement of the specific penicillin compound alone; agencies use cooperative purchasing vehicles to establish manufacturer relationships and negotiate volume pricing across multiple participating jurisdictions and facility types. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the issuing-body model — state purchasing offices and cooperative alliances that aggregate demand across state agencies, counties, municipalities, and other participating government entities to achieve economies of scale on pharmaceutical procurement.

MMCAP's January 2026 Request for Proposal for Generic Multi Source Pharmaceuticals and OTC Products, due March 26, 2026, illustrates current activity under this code. The solicitation covers multiple participating states including Minnesota and Oregon, seeking manufacturers to supply a comprehensive list of generic pharmaceuticals with firm pricing and product specifications (National Drug Codes, SKUs, UPCs, strength, dosage form, and packaging configurations). Vendors must certify cGMP compliance and DSCSA eligibility, maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health 110 and 112, Morris & Dickson Co., LLC), and accept a 3 percent administrative fee. The contract awards multiple vendors based on therapeutic considerations and member-specific needs, with a two-year initial term effective July 1, 2026, and optional extensions. Pricing is weighted at 75 percent of the evaluation, with administrative compliance, EDI capability, and pricing flexibility structures (flat price, net price formats, or WAC-minus) comprising the remainder.